Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rigel PharmaceuticalsFRA:RI2 -2.73%24 Equity-to-Asset is 0.82 as of Jun. 2026, which is 100% above its 10-year median of 0.41. GuruFocus rates FRA:RI2 with a GF Score™ of 24/100 and a GF Value™ of €23.64 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 1,415 Biotechnology companies, Rigel Pharmaceuticals ranks better than 69.05% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Rigel Pharmaceuticals Equity-to-Asset Related Terms
Rigel Pharmaceuticals Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Rigel Pharmaceuticals's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:RI2 vs SGP, OCS, GYRE: Equity-to-Asset Comparison
For the Biotechnology subindustry, Rigel Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rigel Pharmaceuticals Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Rigel Pharmaceuticals's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Rigel Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rigel Pharmaceuticals (FRA:RI2) has a Equity-to-Asset of 0.82 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Rigel Pharmaceuticals and its competitors. This is 100% above median its historical median of 0.41. According to the industry distribution chart, Rigel Pharmaceuticals ranks #438 out of 1415 companies in the Biotechnology industry, placing it in the top 31%.
Is Rigel Pharmaceuticals' Equity-to-Asset too high?
Rigel Pharmaceuticals' current Equity-to-Asset of 0.82 is 100% above median its 10-year median of 0.41. The Biotechnology industry median Equity-to-Asset is 0.68. Rigel Pharmaceuticals' value of 0.82 is 20.6% above this industry median. Based on the distribution chart, Rigel Pharmaceuticals ranks #438 out of 1415 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Rigel Pharmaceuticals has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Rigel Pharmaceuticals' Equity-to-Asset compare to SGP and OCS?
According to the Biotechnology industry distribution chart, Rigel Pharmaceuticals ranks #438 out of 1415 companies for Equity-to-Asset. This puts Rigel Pharmaceuticals in the upper half of its industry. The industry median Equity-to-Asset is 0.68. Rigel Pharmaceuticals' value of 0.82 is 20.6% above this benchmark. While the company's 10-year median is 0.41 vs. the industry median of 0.68, Rigel Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rigel Pharmaceuticals's current Equity-to-Asset of 0.82 is 20.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Rigel Pharmaceuticals and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rigel Pharmaceuticals's current Equity-to-Asset is 0.82, which is 100% above median its own 10-year median of 0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rigel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Rigel Pharmaceuticals (FRA:RI2) is currently considered Significantly Overvalued. The stock's GF Value™ is €23.64, compared to a current price of €34.61 — trading 46.4% above its estimated fair value. The current Equity-to-Asset is 0.82, which is 100% above median its 10-year median of 0.41 and 20.6% above the Biotechnology industry median of 0.68. Rigel Pharmaceuticals' overall GF Score™ is 24/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Rigel Pharmaceuticals (FRA:RI2), the current Equity-to-Asset is 0.82 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rigel Pharmaceuticals (FRA:RI2) Overvalued in 2026?
Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued.
The current stock price of €34.61 is trading 46.4% above its estimated GF Value™ of €23.64.
GuruFocus considers Rigel Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:RI2:
Equity-to-Asset: 0.82 (100% above median its 10-year median of 0.41)
GF Value™: €23.64 vs. price of €34.61 (46.4% above fair value)
Industry Position: 20.6% above the Biotechnology median (#438 of 1415)
No single metric tells the full story. See the FRA:RI2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
24GF Score
Get the complete analysis for FRA:RI2
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RI2 has been successfully added to your 
